Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that when Janssen's Risperdal (risperidone) loses market exclusivity later this year in the United States, the tier status of other antipsychotic drugs will remain largely unchanged in private insurance plans. However, up to 20 percent of surveyed managed care organizations' (MCOs) Medicaid plans indicated that they will remove branded antipsychotics from their formularies, following the patent expiry in the U.S. of Risperdal in June, 2008.

The new Physician & Payer Forum primary market research report entitled The Impact of Risperdal's Patent Expiry on the Antipsychotic Market: Clinician and Payer Attitudes focuses on antipsychotic drug treatment for schizophrenia, bipolar disorder and major depression and the effect that major generic competition will have on future prescribing patterns and reimbursement policies. Although 11 to 20 percent of surveyed MCOs' Medicaid plans will remove branded antipsychotics from their formularies following the patent expiry of Risperdal, the report finds that in most state Medicaid plans, patients that are maintained on brands other than Risperdal will not be required to switch to generic risperidone. For example, surveyed psychiatrists plan to continue their use of one of the higher priced antipsychotics, Bristol-Myers Squibb's Abilify, following the availability of generic risperidone: 60 percent of surveyed psychiatrists will switch none of their schizophrenia patients who are adequately treated with Abilify to generic risperidone. Additionally, 68 percent of surveyed psychiatrists will switch none of their Abilify-treated major depression patients to generic risperidone.

According to the report, surveyed MCO pharmacy directors will direct patients to generic risperidone by introducing step-therapy protocols and will offer samples of generic drugs following the patent expiry of Risperdal. In the treatment of schizophrenia, six of 20 surveyed Medicaid plans will introduce step-therapy protocols covering Eli Lilly's Zyprexa, and five will do the same for AstraZeneca's Seroquel.

"For schizophrenia, bipolar disorder and major depression, psychiatrists will switch more Risperdal patients to generic risperidone than will PCPs," said Sandra Chow, analyst at Decision Resources. "Nearly half of the psychiatrists surveyed indicated they will switch 75-100 percent of their currently treated Risperdal patients to generic risperidone, while PCPs will switch more patients from other brands to generic risperidone. We found that about one-quarter of surveyed PCPs will switch 25-49 percent of their patients from Zyprexa, Seroquel, or Pfizer's Geodon to generic risperidone."

The Impact of Risperdal's Patent Expiry on the Antipsychotic Market: Clinician and Payer Attitudes is based on a U.S. survey of 84 psychiatrists, 70 PCPs, 20 MCO pharmacy directors, and 16 state Medicaid pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Physician & Payer Forum

Physician & Payer Forum is a primary research service from Decision Resources that offers access to high volume-prescribing physicians, specialists, and managed care organization representatives in the United States; analysis of events and survey participants' responses to them; insight into prescribing patterns; and an examination of the implications of events and issues for the pharmaceutical market.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,
emarshall@dresources.com

Bayer/Schering-Plough/Shionogi's Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia

View Now